Abstract: Systems and methods are provided for document handling. Non-vision detection systems may be capable of detecting the dimensions, orientation, and/or position of a single sheet, or multiple stacked sheets. A document scanning arrangement may be capable of double sided scanning for sheets with various characteristics. The systems and methods provided may accommodate high throughput and rapid digitization of various types of documents, at a high quality.

Abstract: Provided are systems and methods for identifying, isolating, and/or aligning sheets. An identification system can facilitate accurate identification of a sheet by (i) vacating one or more components of the system that are not the sheet from a zone of detection, and/or (ii) determining a reference axis of the sheet. An isolation system can facilitate accurate isolation of a sheet by (i) providing targeted air flow, and/or (ii) introducing a wave into the sheet. Identification systems and/or isolation systems described herein may facilitate isolation of sheets that were previously fastened together by one or more fasteners. An alignment system can facilitate accurate alignment of a first sheet at an upstream location relative to a second sheet at a downstream location via machine learning.

Abstract: Method and systems of automated document processing described herein include activating in sequence a plurality of illumination modules of an illumination source to illuminate a document, where the plurality of illumination modules are located at different positions relative to the document. The document can be imaged each time the document is illuminated by an illumination module to provide a plurality of images. A shadow profile of the document can be obtained based on the plurality of images. One or more of a boundary of the document and presence of a fastener attached to the document can be identified using the shadow profile. Any fasteners present may be removed using a robot arm.

Abstract: Compositions and methods for reducing body weight in a subject are disclosed. In one aspect, a method for reducing body weight in a subject comprises: administering to a subject in need thereof a pharmaceutical composition comprising acetaminophen in an amount sufficient for reducing body weight, wherein the acetaminophen is administered orally at a daily dose of 5 mg to 2000 mg, and wherein the composition is formulated in a controlled release formulation. The acetaminophen may be administered alone or in combination with an anti-obesity drug, an appetite suppressant, a diacylglycerol acyltransferase (DGAT) inhibitor, a lipase inhibitor, a onsteroidal anti-inflammatory drugs (NSAIDs), a Type II diabetes agents, anti-insomnia agents or a combination thereof.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: A method for processing information for mentoring service to at-risk people is described. Also describes is a system for implementing the method and a tangible computer readable medium for storing instructions that, when executed by computer processor, causes the computer processor to process information according to the method of the present application.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: A method for processing information for mentoring service to at-risk people is described. Also describes is a system for implementing the method and a tangible computer readable medium for storing instructions that, when executed by computer processor, causes the computer processor to process information according to the method of the present application.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

Abstract: The present application provides a method for determining and managing a subject's risk profile. The risk profile may include the presence or absence of nocturia. The present application further provides methods of using such a risk profile, such methods for underwriting or managing the cost of life insurances or health insurances, methods for calculating risk associated with the risk profile in an insurance candidate/insured subject, and methods for improving lifespan of the insured based on the risk profile.

Abstract: Pharmaceutical compositions for treating bedwetting are disclosed. The pharmaceutical composition comprises one or more analgesic agents in an amount of 1-2000 mg per agent, desmopressin in an amount of 0.01-30 mg and a pharmaceutically acceptable carrier.